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(57)	 ABSTRACT
A microfluidic device is provided for delivering a drug to an
individual. The microfluidic device includes a body that
defines a reservoir for receiving the drug therein. A valve
interconnects the reservoir to an output needle that is insert-
able into the skin of an individual. A pressure source urges the
drug from the reservoir toward the needle. The valve is mov-
able between a closed position preventing the flow of the drug
from the reservoir to the output needle and an open position
allowing for the flow of the drug from the reservoir to the
output needle in response to a predetermined condition in the
physiological fluids of the individual.
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MICROFLUIDIC DEVICE FOR DRUG	 confused. If blood glucose falls, judgment can be impaired
DELIVERY
	
	
and a person could faint. Alternatively, a person can also
become ill if blood glucose levels rise too high, a condition
CROSS REFERENCE TO RELATED	 known as hyperglycemia. Although daily insulin injections
APPLICATION
	
	
5 are a great inconvenience, they are necessary for a diabetics'
survival.
This application is a continuation application of present 	 Most people with diabetes administer their own insulin
U.S. application Ser. No. 10/640,345, filed Aug. 13, 2003,	 after learning the proper techniques for insulin preparation
(now abandoned) and entitled "Microfluidic Device For Drug 	 and injection. The goal of insulin administration is to give
Delivery," the entirety of which is incorporated herein by io enough insulin to cover the amount of food (especially car-
reference.	 bohydrates) that a person consumes so that blood glucose
levels remain normal throughout the day and night. It can be
REFERENCE TO GOVERNMENT GRANT	 appreciated that various factors such as the type of insulin
used, the size of the person, the amount, type, and time that
This invention was made with United States government 15 meals are eaten, and the activity and exercise patterns of the
support awarded by the following agencies: NASA NAGS-	 person effect the amount of insulin that is required by an
1672. The United States has certain rights in this invention. 	 individual. It takes a dedicated patient to continually monitor
their blood glucose level and administer the repeated multiple
FIELD OF THE INVENTION	 injections required. Therefore, an autonomous infusion sys-
20 tem that provides a steady infusion of pharmaceuticals to an
This invention relates generally to microfluidic devices, 	 individual when needed would constitute a significant
and in particular, to a microfluidic device for delivering a 	 advancement in the art.
steady infusion of a drug to an individual.
	
	 Therefore, it is a primary object and feature of the present
invention to provide a microfluidic device that delivers a
BACKGROUND AND SUMMARY OF THE	 25 steady infusion of pharmaceuticals to an individual when
INVENTION	 needed.
It is a further object and feature of the present invention to
As is known, the pharmaceutical industry has had limited 	 provide a microfluidic device that delivers a steady infusion
success overcoming the challenges of delivering pharmaceu- 	 of pharmaceuticals to an individual under autonomous con-
ticals to patients. The oral ingestion of pharmaceuticals is 30 trol.
considered the safest, most convenient and most economical 	 It is a still further object and feature of the present invention
method of drug administration. As compared to present alter-	 to provide a microfluidic device for delivering a steady infu-
natives, patient acceptance and adherence to a dosing regimen 	 sion of pharmaceuticals to an individual that is simple to
is typically higher among orally delivered pharmaceuticals. 	 utilize and inexpensive to manufacture.
However, the oral delivery of many pharmaceuticals is not 35	 In accordance with the present invention, a microfluidic
possible because the pharmaceuticals are either too large or 	 device is provided for delivering a drug to an individual. The
too electrically charged to pass through the small intestine to 	 microfluidic device includes a reservoir for receiving a drug
reach the bloodstream. In addition, many pharmaceuticals 	 therein and an output needle. The output needle has an input
that are unable to withstand the environment of the digestive 	 in communication with the reservoir and an output receivable
tract or to penetrate the dermis need to be injected into the 40 within the individual. A pressure source is engageable with
patient (e.g. insulin, proteins). As hereinafter described, the 	 the reservoir for urging the drug from the reservoir through
injection of pharmaceuticals into a patient has certain draw- 	 the output needle.
backs.	 The microfluidic device includes a flexible membrane iso-
By way of example, insulin is often used to treat diabetes,	 lating the pressure source from the reservoir. A valve opera-
a disorder of metabolism. Most of the foods eaten by indi- 45 tively connects the input of the output needle and the reser-
viduals are broken down in the body into glucose, the form of 	 voir. The valve defines a chamber having an input
sugar in the blood. Glucose is the main source of fuel for the	 communicating with the reservoir and an output communi-
body. After digestion, the glucose passes into the bloodstream	 cating with the input of the output needle. The valve also
where it is used by the cells for growth and energy. For 	 includes a flexible membrane dividing the chamber into a first
glucose to get into cells, insulin must be present. Insulin is a 5o drug flow portion and a second trigger receiving portion. A
hormone that is automatically produced by a healthy pancreas	 trigger is disposed in the trigger receiving portion in the
to move glucose from blood into our cells. In people with 	 chamber of the valve. The trigger has a first configuration
diabetes, however, the pancreas either produces little or no	 preventing the flow of the drug through the chamber and a
insulin, or the cells do not respond appropriately to the insulin	 second configuration allowing for the flow of the drug
that is produced. As a result, glucose builds up in the blood, 55 through the chamber.
overflows into the urine, and passes out of the body. Conse-	 A first sensing needle has an input receivable in the indi-
quently, the body loses its main source of fuel, even though	 vidual and an output within the trigger receiving portion of
the blood contains large amounts of glucose. 	 the chamber. The first sensing needle allows physiological
In order to use the glucose present in the body, a diabetic 	 fluids to pass from the individual to the trigger receiving
must take insulin injections every day. The amount of insulin 60 portion of the chamber. A second sensing needle may also be
taken by an individual must be balanced with the individual's 	 provided. The second sensing needle has an input receivable
food intake and daily activities. Consequently, blood glucose 	 in the individual and an output within the trigger receiving
levels must be closely monitored through frequent blood glu- 	 portion of the chamber. The second sensing needle allows
cose checking to insure that blood glucose levels do not fall 	 physiological fluids to pass from the individual to the trigger
too low or rise too high. When blood glucose levels drop too 65 receiving portion of the chamber in the valve. It is contem-
low from certain diabetes medicines —a condition known as	 plated for the trigger to include a hydrogel post that is expand-
hypoglycemia —a person can become nervous, shaky, and 	 able in response to exposure to a predetermined condition in
US 7,766,902 B2
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the physiological fluid. Hydrogels are stimuli crosslinked
polymeric materials that change their state of swelling, as
manifested by a change in size, in response to chemical and
physical changes in their surrounding environment. It is con-
templated for the hydrogel post to be formed entirely from a
hydrogel material or to be formed from a solid post having the
hydrogel material formed thereabout.
The microfluidic device also may include a second reser-
voir for receiving a bolus of the drug therein. An actuation
device is also provided. The actuation device is movable
between a non-actuated position and an actuated position
wherein the bolus of the drug is urged through the outlet
needle and into the individual.
In accordance with a further aspect of the present inven-
tion, a microfluidic device is provided for delivering a drug to
an individual. The microfluidic device includes a body that
defines a reservoir for receiving the drug therein and a con-
duit. The conduit has an input communicating with the res-
ervoir and an output. An output needle has an input receivable
in the body to communicate with the output of the conduit and
an output outside of the body for insertion into the individual.
A pressure source is engageable with the reservoir for urging
the drug from the reservoir through the output needle.
It is contemplated that the output needle be removable from
the body. In addition, it is contemplated that a flexible mem-
brane isolate the pressure source from the reservoir. The
conduit may include a valve for controlling the flow of the
drug from the reservoir to the output needle. The valve defines
a valve chamber and is movable between a non-actuated
position wherein the valve prevents the flow of the drug from
the reservoir to the output needle and an actuated position
wherein the valve allows for the flow of the drug from the
reservoir to the output needle. A flexible membrane divides
the valve chamber into a first drug flow portion and a second
trigger receiving portion. A trigger is disposed in a trigger
receiving portion of the valve chamber. The trigger has a first
configuration with the valve in the non-actuated position and
a second configuration with the valve in the actuated position.
A first sensing needle has an input receivable in the individual
and an output within the trigger receiving portion of the valve
chamber. The first sensing needle allows physiological fluids
to pass from the individual to the trigger receiving portion of
the valve chamber. The trigger includes a hydrogel post. The
hydrogel post changes the configuration in a response to
exposure to a predetermined condition in the physiological
fluids.
The body may also define a second reservoir for receiving
a bolus of the drug therein. An actuation device is also pro-
vided. The actuation device moves between a non-actuated
position and an actuated position wherein the bolus of the
drug is urged from the second reservoir; through the outlet
needle; and into the individual.
In accordance with a still further aspect of the present
invention, a microfluidic device is provided for delivering a
drug to an individual. The microfluidic device includes a body
defining a reservoir for receiving the drug and an output
needle. The output needle has an input in communication
with the reservoir and an output receivable within the indi-
vidual. An adhesive is provided for affixing the body to the
individual.
The microfluidic device may also include a pressure source
engageable with the reservoir for urging the drug from the
reservoir through the output needle. A docketing station sup-
ports the output needle. The docketing station is removably
connected to the body. A valve defining a chamber intercon-
nects the reservoir and the output needle. The valve is mov-
able between a non-actuated position wherein the valve pre-
Referring to FIGS. 1-4, a microfluidic device in accordance
with the present invention is generally designated by the
4
vents the flow of the drug from the reservoir to the output
needle and an actuated position wherein the valve allows for
the flow of the drug from the reservoir to the output needle.
The valve includes a flexible membrane for dividing the valve
5 chamber into a first drug flow portion and a second trigger
receiving portion. A trigger is positioned within the trigger
receiving portion of the valve chamber. The trigger has a first
configuration with the valve in a non-actuated position and a
second configuration with the valve in the actuated position.
io A first sensing needle has an input receivable in the individual
and an output within the trigger receiving portion of the valve
chamber. The first sensing needle allows physiological fluids
to pass from the individual to the trigger receiving portion of
the valve chamber. The trigger may include a hydrogel post
15 that changes configuration in response to exposure to a pre-
determined condition in the physiological fluids.
The body may also define a second reservoir for receiving
a bolus of the drug therein. An actuation device is also pro-
vided. The actuation device is movable between a non-actu-
2o ated position and an actuated position wherein the bolus of the
drug is urged from the second reservoir, through the outlet
needle, and into the individual.
BRIEF DESCRIPTION OF THE DRAWINGS
25 The drawings furnished herewith illustrate a preferred con-
struction of the present invention in which the above advan-
tages and features are clearly disclosed as well as other which
will be readily understood from the following description of
the illustrated embodiments.30	 In the drawings:
FIG. 1 is a schematic, cross-sectional view showing a first
embodiment of a microfluidic device in accordance with the
present invention;
FIG. 2 is a schematic, cross-sectional view of the microf-35 luidic device of FIG. 1 with the valve in a closed position;
FIG. 3 is a schematic, cross-sectional view of the microf-
luidic device of FIG.1 showing the triggering of the pressure
source;
FIG. 4 is a schematic, cross-sectional view showing the
4o 
microfluidic device of FIG. 1 with the valve in an open posi-
tion;
FIG. 5 is a top plan view showing an alternate embodiment
of a microfluidic device in accordance with the present inven-
45 tion and a torso to which a microfluidic device may be affixed;
FIG. 6 is a schematic, cross-sectional view of the microf-
luidic device of FIG. 5 with the reservoir thereof empty;
FIG. 7 is a schematic, cross-sectional view of the microf-
luidic device of FIG. 5 with the reservoir filled with a drug;
FIG. 8 is a schematic, cross-sectional view of the microf-
So luidic device of FIG. 5 showing the drug being dispensed;
FIG. 9 is a third embodiment of a microfluidic device in
accordance with the present invention;
FIG. 10 is an enlarged, schematic view showing the valve
55 
of the microfluidic device of FIG. 9 in an open position;
FIG. 11 is a schematic, cross-sectional view showing the
valve ofthe microfluidic device of FIG. 9 in a closedposition;
FIG. 12 is a schematic, cross-sectional view showing a
fourth embodiment of the microfluidic device of the present
60 
invention; and
FIG. 13 is a schematic, cross-sectional view of the microf-
luidic device of FIG. 12 dispensing a drug.
DETAILED DESCRIPTION OF THE PREFERRED
EMBODIMENT
65
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reference numeral 10. Microfluidic device 10 includes body 	 prevent drug 16 from flowing from reservoir 14 to outlet
12 formed from polydimethylsiloxane (PDMS) or the like in 	 needle 34. In other words, valve 28 is in the closed position.
any conventional manner such as by compression micro- 	 Hydrogel pressure sources 50 are triggered so as to expand,
molding or rapid prototyping. Body 12 defines reservoir 14 	 FIG. 3, generating pressure on drug 16 within reservoir 14 in
for the receiving and the storage of drug 16 therein. Reservoir 5 body 12. The pressure generated by hydrogel pressure
14 includes output 18 that communicates with input 20 of	 sources 50 urges drug 16 into flow conduit 22 toward valve
flow conduit 22. Output 24 of flow conduit 22 communicates	 28.
with the input 26 of valve 28. Output 30 of valve 28 commu-	 As heretofore described, hydrogel trigger 42 is responsive
nicates with input 32 of outlet needle 34 that projects from 	 to a predetermined condition within the physiological fluid
body 12. Outlet needle 34 includes outlet end 36 that is io flowing into trigger receiving portion 40 of the valve chamber
injectable into an individual, as hereinafter described. 	 of valve 28 through sensing needles 44. By way of example,
Valve 28 includes a valve chamber defined by drug flow 	 it is contemplated that hydrogel trigger 42 shrink in response
portion 38 and trigger receiving portion 40. Drug flow portion	 to a predetermined concentration of glucose in the physi-
38 and trigger receiving portion 40 of the valve chamber	 ological fluid and that drug 16 within reservoir 14 be insulin.
within valve 28 are isolated from each other by flexible mem- 15 Upon the sensing of a predetermined concentration of glu-
brane 41. As is conventional, valve 28 is movable between a 	 cose in the physiological fluid, hydrogel trigger 42 begins to
closed position, FIGS. 2-3, wherein drug 16 is prevented from 	 shrink. As hydrogel trigger 42 within trigger receiving por-
flowing through drug flow portion 38 of valve 28 to outlet	 tion 40 of the valve chamber of valve 28 shrinks, flexible
needle 34 and an open position, FIGS.1 and 4, wherein drug 	 membrane 41 is withdrawn from input 26 of valve 28 so as to
16 is free to flow through drug flow portion 38 of valve 16 to 20 open valve 28. As a result, drug 16 is allowed to flow through
outlet needle 34. 	 drug flow portion 38 of the valve chamber of valve 28 into and
Hydrogel trigger 42 is positioned within trigger receiving 	 through outlet needle 34, FIG. 4. With valve 28 in the open
portion 40 of the valve chamber within valve 28. Hydrogels	 position, FIG. 4, hydrogel pressure sources 50 continue to
are stimuli crosslinked polymeric materials that change their 	 expand thereby urging flexible membrane 48 into reservoir 14
state of swelling, as manifested by a change in size, in 25 so as to urge the drug 16 therefrom. As described, drug 16
response to chemical and physical changes in their surround- 	 flows from reservoir 14 through flow conduit 22; through
ing environment. In the present invention, hydrogel trigger 42	 drug flow portion 38 of the valve chamber in valve 28;
is sensitive to a predetermined condition within the physi- 	 through outlet needle 34; and into the individual.
ological fluids received in trigger receiving chamber 40 of the	 In the event that the glucose level of the physiological fluid
valve chamber within valve 28. In the disclosed embodiment, so received within trigger receiving portion 40 of the valve
hydrogel trigger 42 shrinks in response to exposure to the 	 chamber in valve 28 drops below a predetermined level,
predetermined condition within the physiological fluids.	 hydrogel trigger 42 will once again expand so as to urge
However, it can be appreciated that hydrogel trigger 42 may 	 flexible membrane 41 against input 26 to valve 28, thereby
expand in response to such condition if so desired. 	 closing valve 28. As a result, the flow of drug 16 to the
The valve 28 further includes a plurality of sensing needles 35 individual is stopped.
44 extending between trigger receiving portion 40 of the	 Referring to FIG. 5, an alternate embodiment of a microf-
valve chamber within valve 28 and the environment outside 	 luidic device in accordance with the present invention is
body 12. Sensing needles 44 may take the form of an array of 	 generally designated by the reference numeral 60. Similar to
micro-needles or a single needle similar to outlet needle 34. 	 microfluidic device 10, it is intended that microfluidic device
Sensing needles 44 allow physiological fluids to flow into 40 60 be affixed to the skin of individual 62. Microfluidic device
trigger receiving portion 40 of the valve chamber within valve	 60 includes body 64 that defines reservoir 66 for receiving
28, for reasons hereinafter described. 	 drug 68 therein. In addition, body 64 defines a pressure source
Microfluidic device 10 further defines pressure source cav-	 cavity 70 for receiving a plurality of pressure sources 72, as
ity 46 that is isolated from reservoir 14 by flexible membrane	 hereinafter described. In addition, trigger 74 is positioned
48. A plurality of hydrogel pressure sources 50 are spatially 45 within the pressure source cavity 70 in body 64 of microflu-
disposed within pressure source cavity 46. Hydrogel pressure	 idic device 60. Ports 76 and 78 are provided in body 64 to
sources 50 are responsive to a trigger such as a buffer solution 	 allow communication with reservoir 66 and pressure source
injectable into pressure source cavity 46 either during or after	 cavity 70, respectively, with a syringe or the like.
fabrication of body 12. In the depicted embodiment, the 	 Reservoir 66 and pressure source cavity 70 are separated
buffer solution injected into pressure source cavity 46 and 5o by first flexible membrane 80. In addition, pressure source
body 12 causes hydrogel pressure sources 50 to expand and	 cavity 70 is isolated from input 82 of needle 84 by second
exert a pressure on flexible membrane 48, for reasons here-	 flexible membrane 86. Second flexible membrane 86 is
inafter described. 	 biased over input 82 to outlet needle 84 by trigger 74, as
In operation, microfluidic device 10 is positioned adjacent	 hereinafter described. Outlet needle 84 also includes output
the skin of an individual and urged therein such that input 36 55 88 that is receivable within the skin of an individual 62
of outlet needle 34 communicates with the subcutaneous	 In operation, reservoir 66 is filed with drug 68 through port
layer of the skin of an individual. Sensing needles 44 are of 	 76 in body 64. Thereafter, body 64 is positioned against the
sufficient depth within the skin of the individual such that 	 skin of individual 62 such that output 88 of outlet needle 84
physiological fluids may flow into trigger receiving portion 	 communicates with the subcutaneous layer of the skin. In
40 of the valve chamber within valve 28. Adhesive 52 is 60 order to trigger operation of microfluidic device 60, buffer
provided along the lower surface 54 of body 12 so as to affix 	 solution 98 is injected into pressure source cavity 70 through
microfluidic device 10 to the outer surface of the skin of the 	 port 78 in body 64, FIG. 7. With buffer solution 98 within
individual.	 pressure source cavity 70, pressure sources 72 expand in
In its initial configuration, FIGS. 2-3, hydrogel trigger 42 	 response thereto. Simultaneously, trigger 74 begins to shrink.
within trigger receiving portion 40 of the valve chamber of the 65 As trigger 74 shrinks, second flexible membrane 86 is with-
valve 28 urges flexible membrane 41 over input 26 to drug 	 drawn from input 82 of outlet needle 84 such that reservoir 66
flow portion 38 of the valve chamber within valve 28 so as to	 is in communication with input 82 of outlet needle 84. As a
US 7,766,902 B2
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result, as pressure sources 72 continue to expand, first flexible
membrane 80 is urged into reservoir 66 causing drug 68 to
flow from reservoir 66 into and through outlet needle 84, FIG.
8. Pressure sources 72 continue to expand at a constant rate
over time such that drug 68 is dispensed into the subcutaneous
layer of the skin of individual 62 at a constant rate over a
predetermined time period.
It can be appreciated, that once drug 68 is expunged from
reservoir 66, buffer solution 98 may be removed from pres-
sure source cavity 70 so as to cause pressure sources 72 and
trigger 74 to return to their original configuration. If another
dosage of drug 66 is required, the process may be repeated.
Referring to FIGS. 9-11, a still further embodiment of a
microfluidic device in accordance with the present invention
is generally designated by the reference numeral 100. Microf-
luidic device 100 includes body 102 defining first reservoir
104 for receiving drug 106 therein. In addition, body 102
defines second reservoir 108 for receiving a bolus of drug 106
therein. Flexible membrane 110 overlaps reservoir 108 and
defines a bistable button, for reasons hereinafter described.
Second reservoir 108 communicates with outlet needle 112
through flow conduit 114.
First reservoir 104 communicates with outlet needle 112
through valve 116. Valve 116 includes inlet 118 and outlet
120 that communicates with outlet needle 112. Valve 116 is
movablebetween a closedposition, FIG. 11, whereinthe drug
106 is maintained within reservoir 104, FIG. 11, and an open
position, FIG. 10 wherein drug 106 of reservoir 104 is free to
flow through valve 116 into outlet needle 112.
Valve 116 includes drug flow chamber 122 disposed
between input 118 and output 120 of valve 116 and trigger
receiving chamber 128. Trigger receiving chamber 128 is
isolated from drug flow chamber 122 by flexible membrane
124. Hydrogel trigger 126 is positioned within trigger receiv-
ing chamber 128 of valve 116. Hydrogel trigger 126 has a first
enlarged configuration, FIG. 11, wherein hydrogel trigger
126 engages flexible membrane 124 and urges flexible mem-
brane 124 against input 118 to valve 116 such that valve 116
is in its closed position, and a second retracted configuration,
FIG. 10, wherein flexible membrane 124 is spaced from input
118 to valve 116 such that valve 116 is in its open position.
Valve 116 further includes a plurality of sensing needles
130 having inputs extending from body 102 of microfluidic
device 100 and outputs in communication with trigger receiv-
ing chamber 128 of valve 116. It is intended that sensing
needles 130 allow for the physiological fluids to pass from an
individual into trigger receiving chamber 128 in valve 116.
In operation, valve 116 is initially in its closed position,
FIG. 11, such that drug 106 is unable to flow from reservoir
104 to output needle 112. Body 102 of microfluidic device
106 is positioned against the skin of an individual such that
outlet needle 112 is inserted into and communicates with the
subcutaneous layer of the skin and such that sensing needles
130 allow physiological fluids to flow into trigger receiving
chamber 128 of valve 116. In response to a predetermined
condition of the physiological fluid flowing into trigger
receiving chamber 128 of valve 116, hydrogel trigger 126
retracts from its expanded configuration, FIG. 11, to its
retracted configuration, FIG. 10, thereby opening valve 116.
With valve 116 open, drug 106 is free to flow through valve
116 and into outlet needle 112. As a result, drug 106 flows
from outlet 132 of outlet needle 112 into the subcutaneous
layer of skin of the individual. If the predetermined condition
of the physiological fluid in trigger receiving chamber 128 of
valve 116 is relieved, hydrogel trigger 126 returns to its
expanded configuration, FIG. 11, so as to close valve 116.
8
With valve 116 in the closed position, drug 106 in reservoir
104 no longer flows through outlet needle 112 into the indi-
vidual.
In such circumstances when a bolus of the drug 106 is
5 immediately needed by the individual, it is contemplated to
allow the individual to depress flexible membrane 110
thereby urging drug 106 from second reservoir 108 into flow
conduit 114. Drug 106 flows through flow conduit 114 and
10 outlet needle 112 into the subcutaneous layer of skin of the
individual.
Referring to FIGS. 12 and 13, a still further embodiment of
the microfluidic device of the present invention is generally
designated by the reference numeral 140. Microfluidic device
15 140 includes docking station 142 and body 144. Body 144
defines reservoir 146 for receiving drug 148 therein. In addi-
tion, body 144 includes pressure source chamber 150 for
receiving aplurality of hydrogel pressure sources 152 therein.
Hydrogel pressure sources 152 expand in response to expo-
20 sure to a predetermined buffer solution. Body 144 further
defines flow conduit 154 which includes inlet 156 communi-
cating with reservoir 146 in body 144 and outlet 158 commu-
nicating with outer surface 160. Pierceable membrane 162
may be provided in flow conduit 154 to prevent the undesired
25 flow of drug 148 from reservoir 146.
Docking station 142 includes base 164 extending along a
first axis and an alignment support 166 extending normal
thereto. Needle 168 extends through and is supported by base
30 164. Needle 168 includes inlet end 170 on first side 172 of
base 164 and outlet end 174 on second side 176 of base 164.
It is contemplated to provide an adhesive on second side 176
of base 164 for affixing docking station 142 to the skin of an
individual.
35 In operation, body 144 is positioned against first side 172
of base 164 such that inlet end 170 of needle 168 extends into
flow conduit 154 in body 144 through outlet end 158 thereof.
It is intended that inlet end 170 of needle 168 of docking
40 station 142 pierce membrane 162 within flow conduit 154 so
as to allow drug 148 to flow into and through needle 168.
Alignment wall 166 of docking station 142 facilitates the
alignment of body 144 on first side 172 of base 164 of docking
station 142.
45 With body 144 mounted on docking station 142, microflu-
idic device 140 is positioned against the skin of an individual
such that needle 168 pierces the skin and outlet end 174 of
needle 168 is in communication with the subcutaneous layer
of the skin. Thereafter, a buffer solution is injected into pres-
50 sure source chamber 150 within body 144 so as to cause
hydrogel pressure sources 152 to expand. As hydrogel pres-
sure sources 152 expand, flexible membrane 153 is urged into
reservoir 146. As a result, drug 148 is forced from reservoir
55 
146 through needle 168 into the subcutaneous layer of the
skin of the individual. Once drug 148 has been dispensed
from reservoir 146, body 144 may be removed from the
docking station 142. Thereafter, a replacement body 144 hav-
ing a full dosage of drug 148 in the reservoir 146 may be
60 repositioned on docking station 142, as hereinafter described,
and the process repeated. As described, needle 168 remains
within the individual thereby reducing the frequency that the
individual must insert a needle into his skin.
Various modes of carrying out the invention are contem-
65 plated as being within the scope of the following claims
particularly pointing out and distinctly claiming the subject
matter which is regarded as the invention.
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We claim:
1. A microfluidic device for delivering a drug to an indi-
vidual, comprising:
a body defining a reservoir for receiving the drug;
an output needle having an input in communication with
the reservoir and an output receivable within the indi-
vidual;
an adhesive for affixing the body to the individual;
a pressure source including an hydrogel member expand-
able in response to expo sure to a predetermined physical
property, the hydrogel member engageable with the res-
ervoir and urging the drug from the reservoir through the
output needle as the hydrogel member expands; and
a valve defining a chamber and interconnecting the reser-
voir and the output needle, the valve movable between a
non-actuated position wherein the valve prevents the
flow of the drug from the reservoir to the output needle
and an actuated position wherein the valve allows for the
flow of the drug from the reservoir to the output needle,
the valve including:
10
a flexible membrane for dividing the valve chamber into
a drug flow portion and a trigger receiving portion;
and
a trigger positioned within the trigger receiving portion
of the valve chamber and having a first configuration
with the valve in the non-actuated position and a sec-
ond configuration with the valve in the actuated posi-
tion; and
10 a first sensing needle having an input receivable in theindividual and an output within the trigger receiving
portion of the valve chamber, the first sensing needle
allowing physiological fluids to pass from the individual
to the trigger receiving portion of the valve chamber.
15 2. The microfluidic device of claim 1 wherein the trigger
includes a hydrogel post, the hydrogel post changing configu-
ration in response to exposure to a predetermined condition in
the physiological fluids.
